Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-08
DOI
10.3389/fphar.2021.718281
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 , OPRM1 , and COMT genotype and select opioid therapy
- (2021) Kristine R. Crews et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I—Initial Work-up and Medical Management
- (2021) Lori B. Lerner et al. JOURNAL OF UROLOGY
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II—Surgical Evaluation and Treatment
- (2021) Lori B. Lerner et al. JOURNAL OF UROLOGY
- Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers
- (2020) Pablo Zubiaur et al. BIOMEDICINE & PHARMACOTHERAPY
- Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes
- (2018) Ji-Yeong Byeon et al. ARCHIVES OF PHARMACAL RESEARCH
- Influence of CYP2D6 ,CYP3A4 ,CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers
- (2018) Carmen Belmonte et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans
- (2018) Kyoung-Ah Kim et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Evaluación de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Español de Farmacovigilancia
- (2016) Carmelo Aguirre et al. MEDICINA CLINICA
- Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in theABCG2gene
- (2015) Keisuke Gotanda et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forUGT1A1and Atazanavir Prescribing
- (2015) RS Gammal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines forCYP3A5Genotype and Tacrolimus Dosing
- (2015) KA Birdwell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update
- (2014) L B Ramsey et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing
- (2014) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenomics Knowledge for Personalized Medicine
- (2012) M Whirl-Carrillo et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamsulosin Exposure Is Significantly Increased by theCYP2D6*10/*10Genotype
- (2012) Chang-Ik Choi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The role of combination medical therapy in benign prostatic hyperplasia
- (2008) K A Greco et al. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started